What are the targets of cabozantinib?

Cabozantinib is a multi-target tyrosine kinase inhibitor that mainly acts on multiple key signaling pathways in tumor cells. It has the ability to inhibit multiple targets, thereby inhibiting the growth, spread and angiogenesis of tumor cells, thus playing an anti-cancer role.

The main targets of cabozantinib include the following categories:

1.MET：MET is an important receptor tyrosine kinase, involved in regulating the proliferation, migration and invasion of tumor cells. Cabozantinib can effectively inhibit the activity of MET, thereby blocking the growth and metastasis of tumor cells.

2.VEGFR2:VEGFR2 is a type of vascular endothelial growth factor receptor, involved in regulating angiogenesis and the formation of new blood vessels. Cabozantinib can inhibit the activity of VEGFR2, thereby inhibiting tumor angiogenesis and reducing the blood supply to the tumor.

3.RET: RET is an important receptor tyrosine kinase that plays an important role in tumors such as thyroid cancer. Cabozantinib can inhibit the activity of RET, thereby inhibiting the growth and metastasis of tumors such as thyroid cancer.

4.KIT：KIT is a receptor tyrosine kinase that is highly expressed in a variety of tumors. Cabozantinib can inhibit the activity of KIT, thereby inhibiting the proliferation and migration of tumor cells.

5.AXL：AXL is a receptor tyrosine kinase involved in regulating the adhesion, migration and invasion of tumor cells. Cabozantinib can inhibit the activity of AXL, thereby inhibiting tumor metastasis and invasion.

In summary, cabozantinib, as a multi-target tyrosine kinase inhibitor, mainly acts on MET, VEGFR2, RET, KIT, AXL and other key signaling pathways, thereby inhibiting the growth, spread and angiogenesis of tumor cells, and has a wide range of anti-cancer effects.